Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12238028rdf:typepubmed:Citationlld:pubmed
pubmed-article:12238028lifeskim:mentionsumls-concept:C0018956lld:lifeskim
pubmed-article:12238028lifeskim:mentionsumls-concept:C0947647lld:lifeskim
pubmed-article:12238028lifeskim:mentionsumls-concept:C0032893lld:lifeskim
pubmed-article:12238028lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:12238028lifeskim:mentionsumls-concept:C1527362lld:lifeskim
pubmed-article:12238028pubmed:issue13lld:pubmed
pubmed-article:12238028pubmed:dateCreated2002-9-19lld:pubmed
pubmed-article:12238028pubmed:abstractTextAutologous stem cell transplantation has been successfully used in treatment of various hematological malignancies and solid tumors in children and adults. Published data have confirmed that bone marrow harvests and peripheral blood stem cell collections frequently contain a significant number of tumor cells. Contaminating tumor cells can contribute to the disease relapse in posttransplant period, so attempts are made to eliminate contaminating tumor cells from autografts. In the case of allogenic transplantation, T-lymphocytes depletion from graft decreases the risk of the graft versus host disease after transplantation. In this article we comment techniques available and method used for elimination of tumor cells. Commentary is aimed on potential benefits and risks of every method.lld:pubmed
pubmed-article:12238028pubmed:languageczelld:pubmed
pubmed-article:12238028pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12238028pubmed:citationSubsetIMlld:pubmed
pubmed-article:12238028pubmed:statusMEDLINElld:pubmed
pubmed-article:12238028pubmed:monthJullld:pubmed
pubmed-article:12238028pubmed:issn0008-7335lld:pubmed
pubmed-article:12238028pubmed:authorpubmed-author:HrubáAAlld:pubmed
pubmed-article:12238028pubmed:authorpubmed-author:EckschlagerTTlld:pubmed
pubmed-article:12238028pubmed:authorpubmed-author:Mat?jckováSSlld:pubmed
pubmed-article:12238028pubmed:authorpubmed-author:SumerauerDDlld:pubmed
pubmed-article:12238028pubmed:issnTypePrintlld:pubmed
pubmed-article:12238028pubmed:volume141lld:pubmed
pubmed-article:12238028pubmed:ownerNLMlld:pubmed
pubmed-article:12238028pubmed:authorsCompleteYlld:pubmed
pubmed-article:12238028pubmed:pagination411-6lld:pubmed
pubmed-article:12238028pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12238028pubmed:meshHeadingpubmed-meshheading:12238028...lld:pubmed
pubmed-article:12238028pubmed:meshHeadingpubmed-meshheading:12238028...lld:pubmed
pubmed-article:12238028pubmed:meshHeadingpubmed-meshheading:12238028...lld:pubmed
pubmed-article:12238028pubmed:meshHeadingpubmed-meshheading:12238028...lld:pubmed
pubmed-article:12238028pubmed:meshHeadingpubmed-meshheading:12238028...lld:pubmed
pubmed-article:12238028pubmed:year2002lld:pubmed
pubmed-article:12238028pubmed:articleTitle[Manipulation of hematopoietic stem cell grafts and their use in clinical practice].lld:pubmed
pubmed-article:12238028pubmed:affiliationKlinika d?tské onkologie 2. LF UK a FNM, Praha UHKT, Praha.lld:pubmed
pubmed-article:12238028pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12238028pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:12238028pubmed:publicationTypeReviewlld:pubmed
pubmed-article:12238028pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed